Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

NCT07311746 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

T-cell Prolymphocytic Leukemia
Refractory T-Cell Prolymphocytic Leukemia

Interventions

DRUG: Ruxolitinib
DRUG: Cladribine
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center